Physician profile
Daniel Grinberg
NPI 1851390942
$5,035.14
in general payments reported to CMS, 2019-2025
30 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 86% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $499 · 2021: $214 · 2022: $441 · 2023: $1,053 · 2024: $1,008 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481 · Education: $73.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.83 |
| Education | $73.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $789.49 | 2019-2025 | Nucala |
| Aerin Medical INC. | $708.06 | 2024-2025 | |
| Optinose US, INC. | $462.54 | 2019-2025 | |
| Genzyme Corporation | $456.99 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $404.12 | 2019-2025 | Dupixent |
| Intersect Ent, INC. | $347.80 | 2020-2022 | |
| Kaleo, INC. | $306.92 | 2020-2024 | Auvi-Q |
| Astrazeneca Pharmaceuticals Lp | $210.92 | 2019-2023 | Fasenra |
| Novartis Pharmaceuticals Corporation | $198.93 | 2019-2024 | |
| Inspire Medical Systems, INC. | $176.40 | 2023-2024 | Inspire |
| Medtronic, INC. | $132.04 | 2024-2025 | Pteye Parathyroid Detection System, Propel |
| Ars Pharmaceuticals Operations, INC. | $120.10 | 2025 | Neffy |
| Grifols USA, LLC | $110.41 | 2023-2024 | Xembify |
| Stryker Corporation | $81.89 | 2019 | |
| Amgen INC. | $70.34 | 2025 | Tezspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $65.60 | 2023-2024 | Ryaltris |
| Takeda Pharmaceuticals U.S.A., INC. | $65.45 | 2022-2023 | Cuvitru |
| Acclarent, INC | $46.57 | 2020-2021 | |
| Genentech USA, INC. | $40.34 | 2023-2024 | Xolair |
| Pfizer INC. | $37.49 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.57 | 2020 | |
| Ethicon US, LLC | $30.03 | 2022 | |
| Alk-Abello, INC | $24.46 | 2020 | |
| Blueprint Medicines Corporation | $24.16 | 2023 | Ayvakit |
| Csl Behring | $19.11 | 2025 | Andembry |
| Hologic Sales and Service, LLC | $16.35 | 2024 | Coolseal Generator |
| Paratek Pharmaceuticals, INC. | $14.76 | 2025 | Xhance |
| Phathom Pharmaceuticals, INC. | $14.25 | 2025 | Voquezna |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Grinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.